BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 2844392)

  • 1. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
    Carter GL; Cory JG
    Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
    Cory JG; Carter GL
    Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo growth of mouse leukemia L1210 cells with metabolic alterations in the subunits of ribonucleotide reductase.
    Somerville L; Cory AH; Cory JG
    In Vivo; 2002; 16(3):175-7. PubMed ID: 12182112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
    Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
    Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
    Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
    Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribonucleotide reductase from wild type and hydroxyurea-resistant chinese hamster ovary cells.
    Lewis WH; Wright JA
    J Cell Physiol; 1978 Oct; 97(1):87-97. PubMed ID: 568630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxyribonucleotide metabolism and cyclic AMP resistance in hydroxyurea-resistant S49 T-lymphoma cells.
    Albert DA; Gudas LJ; Nodzenski E
    J Cell Physiol; 1987 Feb; 130(2):262-9. PubMed ID: 3029148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of N-hydroxy-N'-aminoguanidine derivatives on ribonucleotide reductase activity, nucleic acid synthesis, clonogenicity, and cell cycle of L1210 cells.
    Weckbecker G; Weckbecker A; Lien EJ; Cory JG
    Cancer Res; 1987 Feb; 47(4):975-8. PubMed ID: 2433036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased ribonucleotide reductase activity in hydroxyurea-resistant mosquito cells.
    Gerenday A; Shih KM; Herman CC; Fallon AM
    Arch Insect Biochem Physiol; 2001; 46(1-2):19-25. PubMed ID: 11276057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
    Weckbecker G; Weckbecker A; Lien EJ; Cory JG
    J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
    Sato A; Montgomery JA; Cory JG
    Cancer Res; 1984 Aug; 44(8):3286-90. PubMed ID: 6611198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
    Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
    Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-carbamoyloxyurea-resistant Chinese hamster ovary cells with elevated levels of ribonucleotide reductase activity.
    Hards RG; Wright JA
    J Cell Physiol; 1981 Feb; 106(2):309-19. PubMed ID: 7012160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.
    Zhou BS; Hsu NY; Pan BC; Doroshow JH; Yen Y
    Cancer Res; 1995 Mar; 55(6):1328-33. PubMed ID: 7882331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of biochemical modulation of drug combinations directed at the ribonucleotide reductase site on leukemia L1210 cell growth in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Adv Enzyme Regul; 1983; 21():259-70. PubMed ID: 6400064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity.
    Cory JG; Cory AH; Raber NK; Narayanan A; Schneller SW
    Adv Enzyme Regul; 1993; 33():129-40. PubMed ID: 8356905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of inhibition of tumor cell ribonucleotide reductase by 2,3-dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143).
    Cory JG; Fleischer AE
    Cancer Res; 1980 Nov; 40(11):3891-4. PubMed ID: 6781737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.